Best Medical Belgium Inc. to purchase Nordion's Belgian operations
OTTAWA, Feb. 21 /CNW/ - Nordion Inc. (TSX: NDN; NYSE: NDZ), a leading
provider of products and services to the global health science market,
today announced it has signed a share purchase agreement (SPA) with
Best Medical Belgium (Best Medical) for the divestiture of the
Company's Belgian operations, MDS Nordion S.A. Pursuant to the SPA,
Best Medical will acquire all of Nordion's Belgian operations with the
exception of the TheraSphere® business.
Due to the losses incurred in the Belgian operations, Nordion made a
decision in fiscal 2010 to restructure or exit this business. This
decision is aligned with Nordion's strategy to optimize its product
lines by reducing complexity, managing costs and focusing on areas of
the business the Company believes can generate positive long-term
Pursuant to the terms of the SPA, Best Medical will acquire all the
employees in Belgium, including related benefit and pension plans,
except employees directly supporting the TheraSphere® business. Best
Medical will also acquire the Belgian facilities, including current and
future decommissioning and waste disposal requirements. Pursuant to the
SPA, Nordion will leave an amount of capital in the business, currently
estimated to be US$18 million. The final amount will be determined upon
Nordion expects the transaction with Best Medical to be completed in the
next several months. The transaction is subject to customary closing
conditions and the confirmation by the regional government in Belgium
that its decommissioning obligations related to the site being sold
continue, as is, after the transfer of the shares from Nordion to Best
During this process, MDS Nordion S.A. remains focused on delivering
quality product to its customers and managing the business operations.
About Nordion Inc.
Nordion Inc. (TSX: NDN; NYSE: NDZ) is a global specialty health science
company that provides market-leading products used for the prevention,
diagnosis and treatment of disease. We are a leading provider of
medical isotopes, targeted therapies and sterilization technologies
that benefit the lives of millions of people in more than 60 countries
around the world. Our products are used daily by pharmaceutical and
biotechnology companies, medical-device manufacturers, hospitals,
clinics and research laboratories. Nordion has more than 600 highly
skilled employees in four locations. Find out more at www.nordion.com.
Forward Looking Statements
Certain statements contained in this news release constitute
"forward-looking statements". These statements are based on current
beliefs and assumptions of management, however are subject to known and
unknown risks, uncertainties and other factors that may cause actual
results to differ materially from the forward-looking statements in
this news release. For additional information with respect to certain
of these beliefs, assumptions, risks and uncertainties, please refer to
Nordion's Annual Information Form for fiscal 2010 available on SEDAR at
www.sedar.com and on EDGAR on www.sec.gov.
2010 Annual Financial Statements
Nordion filed its 2010 Annual Report, including its audited consolidated
financial statements and notes for the year ended October 31, 2010, and
related management's discussion and analysis on January 20, 2011. To
view the Company's annual disclosure documents, visit Nordion's profile
on www.sedar.com or Nordion's website at www.nordion.com/investors/annual_reports.asp. Print copies can be ordered on the Company's website at http://www.nordion.com/investors/report_request_form.asp.
SOURCE Nordion Inc.
For further information:
(613) 592-3400 x. 2414